Package TEQR. R topics documented: February 5, Version Date Title Target Equivalence Range Design Author M.

Similar documents
Package appnn. R topics documented: July 12, 2015

Package citccmst. February 19, 2015

Package QualInt. February 19, 2015

Comprehensive evaluation of CRM, mtpi, and 3+3 relative to a benchmark

ivlewbel: Uses heteroscedasticity to estimate mismeasured and endogenous regressor models

Package seqdesign. April 27, Version 1.1 Date

Package AbsFilterGSEA

Package ExactCIdiff. February 15, 2013

Package wally. May 25, Type Package

Package HAP.ROR. R topics documented: February 19, 2015

Package propoverlap. R topics documented: February 20, Type Package

Package cssam. February 19, 2015

Package ORIClust. February 19, 2015

Package CompareTests

Package singlecase. April 19, 2009

Package speff2trial. February 20, 2015

A web application for conducting the continual reassessment method

Package p3state.msm. R topics documented: February 20, 2015

Bayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity. Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi

Package inctools. January 3, 2018

Package rvtdt. February 20, rvtdt... 1 rvtdt.example... 3 rvtdts... 3 TrendWeights Index 6. population control weighted rare-varaints TDT

Package noia. February 20, 2015

Package prognosticroc

Package GANPAdata. February 19, 2015

Package inote. June 8, 2017

Package clust.bin.pair

Package ordibreadth. R topics documented: December 4, Type Package Title Ordinated Diet Breadth Version 1.0 Date Author James Fordyce

Package longroc. November 20, 2017

Package BUScorrect. September 16, 2018

Package hei. August 17, 2017

Package StepReg. November 3, 2017

Package tumgr. February 4, 2016

Common Errors. ClinicalTrials.gov Basic Results Database

Package nopaco. R topics documented: April 13, Type Package Title Non-Parametric Concordance Coefficient Version 1.0.

PHASE 1 CLINICAL TRIALS: DESIGNS AND CONSIDERATIONS. Sarit Assouline, MD, MSc, FRCPC Associate professor, McGill University Jewish General Hospital

Table of Contents. Section 1: Pharmacists Work Status and Demographics: All Licensed

Package mediation. September 18, 2009

Package ICCbin. November 14, 2017

Endpoints in Gynecologic Cancer Clinical Trials

Package xseq. R topics documented: September 11, 2015

Package SAMURAI. February 19, 2015

Package ega. March 21, 2017

Package pollen. October 7, 2018

Package EpiEstim. R topics documented: February 19, Version Date 2013/03/08

Package mdsdt. March 12, 2016

Designs for Partially-Ordered Phase I Trials : Combinations of Agents and Groups of Patients. Mark Conaway University of Virginia

The University of Texas MD Anderson Cancer Center Division of Quantitative Sciences Department of Biostatistics. CRM Suite. User s Guide Version 1.0.

Introduction to SPSS. Katie Handwerger Why n How February 19, 2009

Package PELVIS. R topics documented: December 18, Type Package

Package RNAsmc. December 11, 2018

Package Actigraphy. R topics documented: January 15, Type Package Title Actigraphy Data Analysis Version 1.3.

Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials

Package DeconRNASeq. November 19, 2017

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company

Package memapp. R topics documented: June 2, Version 2.10 Date

The CAP Method for Assessing Surface Dust Samples for Mold

PKPD modelling to optimize dose-escalation trials in Oncology

Workshop # 3 : Application of Bayesian Statistics in early development studies

Package influence.me

BALTIMORE COUNTY HIV/AIDS EPIDEMIOLOGICAL PROFILE Fourth Quarter Data reported throuh December 31, 2007

Package TargetScoreData

Combination dose finding studies in oncology: an industry perspective

Package MSstatsTMT. February 26, Title Protein Significance Analysis in shotgun mass spectrometry-based

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Cabozantinib (Cometriq )

Package Interpol. R topics documented: February 19, Type Package. Title Interpolation of amino acid sequences. Version

Package ncar. July 20, 2018

Speaker: Clement Ma, PhD, Dana-Farber/Boston Children s Cancer and Blood Disorders Center, Harvard Medical School

Package frailtyhl. February 19, 2015

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Package BCRA. April 25, 2018

Maria-Athina Altzerinakou1, Xavier Paoletti2. 9 May, 2017

Package ClusteredMutations

Estimating the number of components with defects post-release that showed no defects in testing

Package CorMut. January 21, 2019

A modified Hierarchical Continuous Reassessment Method (CRM) applied to a first-in-man study.

CONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 10003

UNTHSC. Institutional Animal Care and Use Committee

Package sbpiper. April 20, 2018

Package preference. May 8, 2018

M. Kratzel. Two Examples of interactive elearning

Modifying Food Packages

First author. Title: Journal

Package CTT. February 4, 2018

Using the package crmpack: introductory examples

The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs

Vega: Variational Segmentation for Copy Number Detection

ENERGY EFFICIENCY AND DEMAND MANAGEMENT PROCEDURE GENERAL CUSTOMER BASELINE LOAD ( CBL ) Verification Methodology

GridMAT-MD: A Grid-based Membrane Analysis Tool for use with Molecular Dynamics

Linear Regression in SAS

The use of random projections for the analysis of mass spectrometry imaging data Palmer, Andrew; Bunch, Josephine; Styles, Iain

Technical Bulletin. Technical Information for Lyra Direct Strep Assay

Package bionetdata. R topics documented: February 19, Type Package Title Biological and chemical data networks Version 1.0.

User Guide. Association analysis. Input

Bayes Factors for t tests and one way Analysis of Variance; in R

Using mixture priors for robust inference: application in Bayesian dose escalation trials

ASCO Annual Meeting 2013, May 31 June , Chicago, IL

Package MethPed. September 1, 2018

Transcription:

Package TEQR Version 6.0-0 Date 2016-02-02 Title Target Equivalence Range Design Author M. Suzette Blanchard February 5, 2016 Depends Maintainer M. Suzette Blanchard <sblanchard@coh.org> The TEQR package contains software to calculate the operating characteristics for the TEQR and the ACT designs.the TEQR (toxicity equivalence range) design is a toxicity based cumulative cohort design with added safety rules. The ACT (Activity constrained for toxicity) design is also a cumulative cohort design with additional safety rules. The unique feature of this design is that dose is escalated based on lack of activity rather than on lack of toxicity and is de-escalated only if an unacceptable level of toxicity is experienced. License GPL-2 NeedsCompilation no Repository CRAN Date/Publication 2016-02-05 19:39:07 R topics documented: desc............................................. 2 print.teqrdg......................................... 3 print.teqrocact....................................... 3 print.teqroctox....................................... 4 teqr.dldata......................................... 5 teqr.dldataconact..................................... 6 teqr.mtddataconact................................... 6 teqr.mtddatatox...................................... 7 teqrdg........................................... 7 teqrocact.......................................... 9 teqroctox.......................................... 10 Index 13 1

2 desc desc Descriptive Statistics desc caculates select descriptive statistics for the variable y. desc(y, pcts=c(0.025,0.05,0.95,0.975), nsig=4) y pcts nsig variable of interest selected percentiles, the default is c(0.025,0.05,0.95,0.975) number of significant figures desc prints descriptive statistics including mean, median, standard deviation,range, min, max and selected percentiles. set.seed(1111) OperChar<-teqrOCtox( sim=500, firstdose=2, probt=c(.05,.15,.23,.34,.51,.76), cohortsize=3, MaxNoCohorts=30, MTDss=12, ptarget=.2, eq1=.05, eq2=.05, tootoxic=.34) OperChar TotalN<-rep(NA,500) for (i in 1:500){ TotalN[i]<-sum(OperChar$DLdata$dllength[OperChar$DLdata$simNo==i]) } desc(totaln)

print.teqrdg 3 print.teqrdg print.teqrdg Print file for the class teqrdg. ## S3 method for class teqrdg print(x,...) x object of class teqrdg... additional arguments to be passed to lower level functions The output from print.teqrdg is the dose escalation/expansion/de-escalation guidelines table. output<-teqrdg(totaln=12,ptarget=0.2,eq1=0.05,eq2=0.05,tootoxic=0.34) output print.teqrocact print.teqrocact Print file for the class teqrocact. ## S3 method for class teqrocact print(x,...) x object of class teqrocact... additional arguments to be passed to lower level functions

4 print.teqroctox The output from print.teqr is a listing of the operating characteristics for the design as specified by the user. set.seed(1111) OperChar<-teqrOCact( sim=1000, firstdose=2, proba=c(0.50,0.80,0.90), probc=c(0.10,0.10,0.10), cohortsize=3, MaxNoCohorts=30, RP2Dss=6, ptarget=1.00, eq1=0.34, eq2=0.0, toxcon=0.34, llactivity=0.66) OperChar print.teqroctox print.teqroctox Print file for the class teqroctox. ## S3 method for class teqroctox print(x,...) x object of class teqroctox... additional arguments to be passed to lower level functions The output from print.teqroctox is a listing of the operating characteristics for the design as specified by the user.

teqr.dldata 5 set.seed(1111) OperChar<-teqrOCtox( sim=500, firstdose=2, probt=c(0.05,0.15,0.23,0.34,0.51,0.76), cohortsize=3, MaxNoCohorts=30, MTDss=12, ptarget=0.2, eq1=0.05, eq2=0.05, tootoxic=0.34) OperChar teqr.dldata teqroctox intermediate file that creates dose level data teqr.dldata takes the simdata output and creates the dose level data. teqr.dldata(simdata = simdata) simdata includes the simulation results data,simresult, cohortsize,probt, MTDss, ptarget, lowerlimit, upperlimit,tootoxic, the number of simulation (sim) References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121.

6 teqr.mtddataconact teqr.dldataconact teqrocact intermediate file that creates dose level data teqr.dldata takes the simdata output and creates the dose level data. teqr.dldataconact(simdata = simdata) simdata includes the simulation results data, cohortsize,proba,probc, MTDss,pTarget,lowerlimit,upperlimit,tootox toxcon, llactivity, number of simulations (sim) References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121. teqr.mtddataconact teqrocact intermediate file that creates MTD/RP2D level data teqr.mtddatatox takes the simdata and DLdata output and creates the MTD level data. teqr.mtddataconact(simdata = simdata, DLdata = DLdata) simdata DLdata includes the simulation results data, cohortsize,proba,probc, MTDss,pTarget,lowerlimit,upperlimit,tootox toxcon, llactivity, number of simulations (sim) simno,doselevel,stox (no of subjects experiencing activity),dllength (length of the cohort),toxl (lower 95% CI),toxu (upper 95% CI),toxCest (toxicity estimate)

teqr.mtddatatox 7 References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121. teqr.mtddatatox teqroctox intermediate file that creates MTD level data teqr.mtddatatox takes the simdata and DLdata output and creates the MTD level data. teqr.mtddatatox(simdata = simdata, DLdata = DLdata) simdata DLdata includes the simulation results data,simresult, cohortsize,probt, MTDss, ptarget, lowerlimit, upperlimit,tootoxic, the number of simulation (sim) simno,doselevel,stox (no of subjects experiencing a toxicity),dllength (length of the cohort),toxl (lower 95% CI),toxu (upper 95% CI),toxest (toxicity estimate) References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121. teqrdg TEQR Design Dose Escalation/Expansion/De-escalation Guidelines teqrdg prints the TEQR Design Dose Escalation/Expansion/De-escalation Guidelines. The toxicity equivalence range (TEQR) design, is a frequentist up-down design patterned after the modified toxicity probability interval design. The TEQR design extends the well known 3+3 design to allow for: an explicit target range for the dose limiting toxicity (DLT) rate, more than 6 subjects at the maximum tolerated dose (MTD), and specification of a too-toxic rate, which closes a dose level. The TEQR is better than the 3+3 when compared on: 1) the number of times the dose at or nearest the target toxicity level was selected as the MTD, 2) the number of subjects assigned to doses levels,

8 teqrdg at, or nearest the MTD, and 3) the overall trial DLT rate. For sample sizes at the MTD greater that 6 TEQR more accurately and more precisely estimates the rate of toxicity at the MTD because a larger number of subjects are studied at the MTD dose. The TEQR on average uses fewer subjects and provide reasonably comparable results to the continual reassessment method (CRM) in the number of times the dose at or nearest the target toxicity level was selected as the MTD and the number of subjects assigned doses, at, or nearest that target and in overall DLT rate. teqrdg(totaln,ptarget,eq1,eq2,tootoxic) TotalN ptarget eq1 eq2 tootoxic Total Number of subjects being considered at a dose level Target toxicity probability at the MTD. Range subtracted from ptarget to achieve the lower boundary for the equivalence range. Range added to ptarget to achieve the upper boundary for the equivalence range. Probability cutoff at which the toxicity probability is deemed too high to allow further study at that dose level. TEQR outputs a table of dose escalation guidelines (DoseGuideTable) and a table of the underlying probabilities (ProbTable). References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121. output<-teqrdg(totaln=12,ptarget=0.2,eq1=0.05,eq2=0.05,tootoxic=0.34) output

teqrocact 9 teqrocact Activity Constrained for Toxicity (ACT) design trial simulator The activity constrained for toxicity (ACT) design implements a cumulative cohort design in conjunction with safety rules similar to those from the toxicity equivalence range design or the modified toxicity probability interval design. The unique feature of this design is that dose is escalated based on lack of activity rather than on lack of toxicity and is de-escalated only if an unacceptable level of toxicity is experienced. teqrocact(sim,firstdose,proba,probc,cohortsize,maxnocohorts, RP2Dss,pTarget,eq1,eq2,tootoxic,toxcon,llactivity) sim Number of trial simulations desired. We recommend at least 1000. The example runs 500 to meet R package time limits. firstdose Dose level where the trial will start. The default setting is 2. proba probc Vector of activities associated with the dose elvels from 1 to n Vector of toxicities associated with the dose levels from 1 to n (e.g probt=c(0.05,0.15,0.23,0.34,0.51,0.76) for dose levels 1 to 6.) cohortsize Number of subjects per cohort. The default setting is 3. MaxNoCohorts Highest number of cohorts possible. The default setting is 30. RP2Dss ptarget eq1 eq2 tootoxic toxcon llactivity Desired sample size at the recommended phase 2 dose (RP2D). The default setting is 12. Target activity probability at the RP2D. Range subtracted from ptarget to achieve the lower boundary for the equivalence range. Range added to ptarget to achieve the upper boundary for the equivalence range. Toxicity probability deemed too high to allow further study at a dose level. Default is set to 1.01 and should not be changed in studing the ACT design. toxicity constaint level Required lower limit of activity to end the trial teqrocact outputs the trial simulation operating characteristics, the simulation data sets, and all the simulation parameters. The simulation operating characteristics include, i) the average number of subjects studied at each dose level, ii) the rate the dose level is chosen as the RP2D (including if there is no RP2D identified), iii) median study sample size, iv) mean study event rate, v) mean event

10 teqroctox rate at the RP2D, vi) mean 95% confidence interval length for the event rate at the RP2D, vii) mean toxicity rate at the the RP2D, viii) proportion of the trials with sample size at or above the level desired at the RP2D, viii) number of simulated trials that do not determine an RP2D and ix) number of simulated trials. Datasets: simdata$simresults gives a line of data for each cohort. The columns are: simno - simulation number, doselevel - dose level, act - the number of subjects that achieve the activity endpoint in the cohort, toxc - the number of subjects that experience a toxicity in the cohort, cumact - the cumulative rate of subjects achieving the activity endpoint at that dose level, and cumtoxc - the cumulative rate of subjects experiencing toxicity at that dose level. DLdata gives a line of data for each dose level. The columns are: simno - simulation number, doselevel - dose level, sact - sum of the number of subjects that achieve the activity endpoint at that doselevel, stoxc - sum of the number of subjects that experience the toxicity endpoint at that dose level, dllength - number of subjects studied at a doselevel, actl - lower limit of the 95% confidence limits for the activity rate, actu - upperlimit of the 95% confidence limits for the activity rate, actest - activity rate estimate at that doselevel, and toxcests - toxicity rate estimate at that doselevel. RP2Ddata gives a line of data at the RP2D dose selected. The columns names are the same as for DLdata. set.seed(1111) OperChar<-teqrOCact( sim=500, firstdose=2, proba=c(0.65,0.75,0.85,1.00), probc=c(0.10,0.20,0.30,0.40), cohortsize=3, MaxNoCohorts=30, RP2Dss=12, ptarget=1.00, eq1=0.34, eq2=0.0, toxcon=0.34, llactivity=0.66) OperChar teqroctox TEQR Design trial simulator

teqroctox 11 teqroctox: Runs clinical trial simulations for the TEQR Design implemented as a Phase I toxicity design and provides a listing of the operating characteristics. The toxicity equivalence range (TEQR) design is a frequentist up-down design patterned after the modified toxicity probability interval design. The TEQR design extends the well known 3+3 design to allow for: an explicit target range for the dose limiting toxicity (DLT) rate, more than 6 subjects at the maximum tolerated dose (MTD), and specification of a too-toxic rate, which closes a dose level. The TEQR is better than the 3+3 when compared on: 1) the number of times the dose at or nearest the target toxicity level was selected as the MTD, 2) the number of subjects assigned to doses levels, at, or nearest the MTD, and 3) the overall trial DLT rate. For sample sizes at the MTD greater that 6 TEQR more accurately and more precisely estimates the rate of toxicity at the MTD because a larger number of subjects are studied at the MTD dose. The TEQR on average uses fewer subjects and provide reasonably comparable results to the continual reassessment method (CRM) in the number of times the dose at or nearest the target toxicity level was selected as the MTD and the number of subjects assigned doses, at, or nearest that target and in overall DLT rate. sim teqroctox(sim,firstdose,probt,cohortsize,maxnocohorts,mtdss,ptarget,eq1,eq2,tootoxic) Number of trial simulations desired. We recommend at least 1000. The example runs 500 to meet R package time limits. firstdose Dose level where the trial will start. The default setting is 2. probt Vector of toxicities associated with the dose levels from 1 to n (e.g probt=c(0.05,0.15,0.23,0.34,0.51,0.76) for dose levels 1 to 6.). We recommend that there be at least 4 dose levels with at least one level below and one level above the level expected to be at the target toxicitiy probability. cohortsize Number of subjects per cohort. The default setting is 3. MaxNoCohorts Highest number of cohorts possible. The default setting is 30. MTDss Desired sample size at the MTD. The default setting is 12. ptarget eq1 eq2 tootoxic Target toxicity probability at the MTD. Range subtracted from ptarget to achieve the lower boundary for the equivalence range. Range added to ptarget to achieve the upper boundary for the equivalence range. Toxicity probability deemed too high to allow further study at a dose level. teqroc outputs the trial simulation operating characteristics, the simulation data sets, and all the simulation parameters. The simulation operating characteristics include, i) the average number of subjects studied at each dose level, ii) the rate the dose level is chosen as the MTD (including if there is no MTD identified), iii) median study sample size, iv) mean study DLT rate, v) mean DLT rate at

12 teqroctox the MTD, vi) mean 95% confidence interval length for the DLT rate at the MTD, vii) proportion of the trials with sample size at or above the level desired at the MTD, viii) number of simulated trials that do not determine an MTD and ix) number of simulated trials. Datasets: simdata$simresults gives a line of data for each cohort. The columns are: simno - simulation number, doselevel - dose level, tox - the number of subjects the experience a toxicity in the cohort, and cumtox - cumulative toxicity in the cohort. DLdata gives a line of data for each dose level. The columns are: simno - simulation number, doselevel - dose level, stox - sum of the number of subjects that experience a toxicity at that doselevel, dllength - number of subjects studied at a doselevel, toxl - lower limit of the 95% confidence limits for toxicity rate, toxu - upperlimit of the 95% confidence limits for toxicity rate, and toxest - toxicity rate estimate at that doselevel. MTDdata gives a line of data at the MTD dose selected. The columns names are the same as for DLdata. References Blanchard MS and Longmate JA, (2011). Toxicity equivalence range design (TEQR): A practical Phase I design. Contemporary Clinical Trials,(32), 114-121. set.seed(1111) OperChar<-teqrOCtox( sim=500, firstdose=2, probt=c(0.05,0.15,0.23,0.34,0.51,0.76), cohortsize=3, MaxNoCohorts=30, MTDss=12, ptarget=0.2, eq1=0.05, eq2=0.05, tootoxic=0.34) OperChar

Index Topic design teqr.dldata, 5 teqr.dldataconact, 6 teqr.mtddataconact, 6 teqr.mtddatatox, 7 teqrdg, 7 teqrocact, 9 teqroctox, 10 Topic print print.teqrdg, 3 print.teqrocact, 3 print.teqroctox, 4 Topic statistics desc, 2 desc, 2 print.teqrdg, 3 print.teqrocact, 3 print.teqroctox, 4 teqr.dldata, 5 teqr.dldataconact, 6 teqr.mtddataconact, 6 teqr.mtddatatox, 7 teqrdg, 7 teqrocact, 9 teqroctox, 10 13